1. Xu B, Li H, Pi Y, Li K. Global, regional and national burden of Metabolic dysfunction-associated steatotic liver disease in adolescents and adults aged 15-49 years from 1990 to 2021: results from the 2021 Global Burden of Disease study. Front Med (Lausanne). 2025;12:1568211. doi: 10.3389/fmed.2025.1568211. PubMed PMID: 40636383; PubMed Central PMCID: PMC12237898.
2. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-S50. doi: 10.3350/cmh.2024.0431. PubMed PMID: 39159948; PubMed Central PMCID: PMC11925440.
3. Mejia-Guzman JE, Belmont-Hernandez RA, Chavez-Tapia NC, Uribe M, Nuno-Lambarri N. Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. Int J Mol Sci. 2025;26. doi: 10.3390/ijms26072959. PubMed PMID: 40243565; PubMed Central PMCID: PMC11988898.
4. Dua A, Kumari R, Singh M, Kumar R, Pradeep S, Ojesina AI, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front Med (Lausanne). 2025;12:1618275. doi: 10.3389/fmed.2025.1618275. PubMed PMID: 40893881; PubMed Central PMCID: PMC12392282.
5. Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23:117. doi: 10.1186/s12944-024-02108-x. PubMed PMID: 38649999; PubMed Central PMCID: PMC11034170.
6. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608-24. doi: 10.1038/s41580-019-0168-5. PubMed PMID: 31520073.
7. Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Ther. 2022;30:2342-53. doi: 10.1016/j.ymthe.2022.02.021. PubMed PMID: 35192934; PubMed Central PMCID: PMC9171149.
8. Zha X, Gao Z, Li M, Xia X, Mao Z, Wang S. Insight into the regulatory mechanism of m(6)A modification: From MAFLD to hepatocellular carcinoma. Biomed Pharmacother. 2024;177:116966. doi: 10.1016/j.biopha.2024.116966. PubMed PMID: 38906018.
9. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93-5. doi: 10.1038/nchembio.1432. PubMed PMID: 24316715; PubMed Central PMCID: PMC3911877.
10. Cheng W, Li M, Zhang L, Zhou C, Yu S, Peng X, et al. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC. Front Pharmacol. 2022;13:973116. doi: 10.3389/fphar.2022.973116. PubMed PMID: 36120320; PubMed Central PMCID: PMC9471244.
11. Li Q, Xiang J. METTL3 promotes the progression of non-alcoholic fatty liver disease by mediating m6A methylation of FAS. Sci Rep. 2025;15:6162. doi: 10.1038/s41598-025-90419-z. PubMed PMID: 39979577; PubMed Central PMCID: PMC11842791.
12. Li Y, Zhang Q, Cui G, Zhao F, Tian X, Sun BF, et al. m(6)A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes. Genomics Proteomics Bioinformatics. 2020;18:371-83. doi: 10.1016/j.gpb.2020.06.003. PubMed PMID: 33160098; PubMed Central PMCID: PMC8242261.
13. Xie W, Ma LL, Xu YQ, Wang BH, Li SM. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019;518:120-6. doi: 10.1016/j.bbrc.2019.08.018. PubMed PMID: 31405565.
14. Li Y, Zhang D, Gao Y, Wang P, Wang Z, Zhang B, et al. METTL3 exacerbates insulin resistance in hepatocytes by regulating m(6)A modification of cytochrome P450 2B6. Nutr Metab (Lond). 2023;20:40. doi: 10.1186/s12986-023-00762-z. PubMed PMID: 37710320; PubMed Central PMCID: PMC10502999.
15. Peng Z, Gong Y, Wang X, He W, Wu L, Zhang L, et al. METTL3-m(6)A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol Ther. 2022;30:932-46. doi: 10.1016/j.ymthe.2021.09.016. PubMed PMID: 34547464; PubMed Central PMCID: PMC8821937.
16. Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, et al. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun. 2021;12:7213. doi: 10.1038/s41467-021-27539-3. PubMed PMID: 34893641; PubMed Central PMCID: PMC8664922.
17. Dai G, Huang S, Li Y, Tu X, Xia J, Zhou Z, et al. Mettl3-mediated m(6)A modification plays a role in lipid metabolism disorders and progressive liver damage in mice by regulating lipid metabolism-related gene expression. Aging (Albany NY). 2023;15:5550-68. doi: 10.18632/aging.204810. PubMed PMID: 37335109; PubMed Central PMCID: PMC10333091.
18. Liao X, Liu L, Du J, Fan H, Yu Y, Luo Y, et al. METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis. Hepatol Commun. 2025;9. doi: 10.1097/HC9.0000000000000752. PubMed PMID: 40658786; PubMed Central PMCID: PMC12263036.
19. Pan XY, Bi YH, Cheng M, Qian ZZ, Wang L, You HM, et al. METTL3 facilitates hepatic fibrosis progression via m6A-YTHDF2-dependent silencing of GPR161. bioRxiv. 2021:2021.12.15.472749. doi: 10.1101/2021.12.15.472749.
20. Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, et al. m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021;37:109968. doi: 10.1016/j.celrep.2021.109968. PubMed PMID: 34758326; PubMed Central PMCID: PMC8667589.
21. Cui B, Tu S, Li H, Zeng Z, Xiao R, Guo J, et al. METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response. FEBS Open Bio. 2025;15:1144-58. doi: 10.1002/2211-5463.70023. PubMed PMID: 40103332; PubMed Central PMCID: PMC12226423.
22. Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. 2023;4:101144. doi: 10.1016/j.xcrm.2023.101144. PubMed PMID: 37586322; PubMed Central PMCID: PMC10439254.
23. Poh HX, Mirza AH, Pickering BF, Jaffrey SR. Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA. PLoS Biol. 2022;20:e3001683. doi: 10.1371/journal.pbio.3001683. PubMed PMID: 35853000; PubMed Central PMCID: PMC9295969.
24. Smith I, Greenside PG, Natoli T, Lahr DL, Wadden D, Tirosh I, et al. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 2017;15:e2003213. doi: 10.1371/journal.pbio.2003213. PubMed PMID: 29190685; PubMed Central PMCID: PMC5726721.
25. Goel K, Ploski JE. RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives. Front Mol Neurosci. 2022;15:914430. doi: 10.3389/fnmol.2022.914430. PubMed PMID: 35959108; PubMed Central PMCID: PMC9362770.
26. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5:1. doi: 10.1038/s41392-019-0089-y. PubMed PMID: 32296011; PubMed Central PMCID: PMC6946647.
27. Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, et al. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat Commun. 2019;10:4056. doi: 10.1038/s41467-019-12028-5. PubMed PMID: 31492834; PubMed Central PMCID: PMC6731291.
28. Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Munster S, et al. Biological plasticity rescues target activity in CRISPR knock outs. Nat Methods. 2019;16:1087-93. doi: 10.1038/s41592-019-0614-5. PubMed PMID: 31659326.
29. Fazelzadeh Haghighi M, Jafari Khamirani H, Fallahi J, Monfared AA, Ashrafi Dehkordi K, Tabei SMB. Novel insight into FCSK-congenital disorder of glycosylation through a CRISPR-generated cell model. Mol Genet Genomic Med. 2024;12:e2445. doi: 10.1002/mgg3.2445. PubMed PMID: 38722107; PubMed Central PMCID: PMC11080630.
30. Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:W242-W5. doi: 10.1093/nar/gky354. PubMed PMID: 29762716; PubMed Central PMCID: PMC6030908.
31. Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014;30:1473-5. doi: 10.1093/bioinformatics/btu048. PubMed PMID: 24463181; PubMed Central PMCID: PMC4016707.
32. Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 2014;42:W401-7. doi: 10.1093/nar/gku410. PubMed PMID: 24861617; PubMed Central PMCID: PMC4086086.
33. Dara M, Razban V, Talebzadeh M, Moradi S, Dianatpour M. Using CRISPR/Cas9 System to Knock out Exon 48 in DMD Gene. Avicenna J Med Biotechnol. 2021;13:54-7. doi: 10.18502/ajmb.v13i2.5517. PubMed PMID: 34012519; PubMed Central PMCID: PMC8112140.
34. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168. doi: 10.1093/nar/gku936. PubMed PMID: 25300484; PubMed Central PMCID: PMC4267669.
35. Dehairs J, Talebi A, Cherifi Y, Swinnen JV. CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing. Sci Rep. 2016;6:28973. doi: 10.1038/srep28973. PubMed PMID: 27363488; PubMed Central PMCID: PMC4929496.
36. Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology. 2025;82:1303-24. doi: 10.1097/HEP.0000000000000786. PubMed PMID: 38349726; PubMed Central PMCID: PMC11323288.
37. Piao X, Meng D, Zhang X, Song Q, Lv H, Jia Y. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Sci Rep. 2022;12:5672. doi: 10.1038/s41598-022-07746-8. PubMed PMID: 35383205; PubMed Central PMCID: PMC8983752.
38. Haaker MW, Chang JC, Chung BK, Pieper TS, Noe F, Wang T, et al. Cellular Crosstalk Promotes Hepatic Progenitor Cell Proliferation and Stellate Cell Activation in 3D Co-culture. Cell Mol Gastroenterol Hepatol. 2025;19:101472. doi: 10.1016/j.jcmgh.2025.101472. PubMed PMID: 39892785; PubMed Central PMCID: PMC11968293.
39. Messner S, Fredriksson L, Lauschke VM, Roessger K, Escher C, Bober M, et al. Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. Appl In Vitro Toxicol. 2018;4:1-12. doi: 10.1089/aivt.2017.0022. PubMed PMID: 32953943; PubMed Central PMCID: PMC7500040.
40. Sani F, Soufi Zomorrod M, Azarpira N, Soleimani M. The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues. Stem Cells Int. 2023;2023:8836452. doi: 10.1155/2023/8836452. PubMed PMID: 37576406; PubMed Central PMCID: PMC10421706.
41. Ardisasmita AI, Schene IF, Joore IP, Kok G, Hendriks D, Artegiani B, et al. A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use. Commun Biol. 2022;5:1094. doi: 10.1038/s42003-022-04046-9. PubMed PMID: 36241695; PubMed Central PMCID: PMC9568534.